Skip to search formSkip to main contentSkip to account menu

DECAL Regimen

Known as: DECAL, Dexamethasone-Etoposide-Cisplatin-Cytarabine-L'asparaginase Regimen 
A regimen consisting of dexamethasone, etoposide, cytarabine and L-asparaginase, used for the treatment of recurrent childhood Non-Hodgkin lymphoma.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
OBJECTIVES To evaluate the effects of decalcifying agents on programmed cell death ligand 1 (PD-L1) immunohistochemistry (IHC… 
2014
2014
Ziel der Arbeit ist die umfassende Untersuchung des Decal-Prozesses zur Herstellung katalysatorbeschichteter Membranen. Dabei… 
2008
2008
The survival mechanism of dormant tubercle bacilli is unknown; however, accumulating evidence indicates that Mycobacterium… 
Highly Cited
2002
Highly Cited
2002
Despite prolonged therapy (18 months), children with advanced non-lymphoblastic, non-Hodgkin's lymphoma (NHL) treated on previous… 
2002
2002
NOT AVAILABLE POLYMERIC MATERIALS AND FABRICATION METHODS FOR CHEMICAL SENSING. Ralph G. Nuzzo, University of Illinois… 
Highly Cited
2001
Highly Cited
2001
PURPOSE To determine the toxicity and response rate in children treated with dexamethasone, etoposide, cisplatin, high-dose… 
Highly Cited
1998
Highly Cited
1998
Understanding the effects of the external environment on bacterial gene expression can provide valuable insights into an array of… 
1986
1978
1978
This paper describes the development and the application o f the Design Communication Algorithm (DECAL) which is currently being…